Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia

Endocrine Journal

Volumn 58, Issue 5, 2011, Pages 381-393

  Stanojevic, Boban ^a,b,c   Dzodic, Radan ^b   Saenko, Vladimir ^a   Milovanovic, Zorka ^b   Pupic, Gordana ^b   Zivkovic, Ognjen ^b   Markovic, Ivan ^b   Djurisic, Igor ^b   Buta, Marko ^b   Dimitrijevic, Bogomir ^c   Rogounovitch, Tatiana ^a   Mitsutake, Norisato ^a   Mine, Mariko ^a   Shibata, Yoshisada ^a   Nakashima, Masahiro ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

BRAF mutation; Disease free survival; Papillary thyroid carcinoma; Prognosis

Indexed keywords

B RAF KINASE; GENOMIC DNA; PROTEIN PATCHED; PROTEIN PATCHED 1; PROTEIN PTC3; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; B RAF KINASE GENE; CANCER STAGING; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; FEMALE; FOLLOW UP; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE RAS; PHENOTYPIC VARIATION; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; PTC1 GENE; PTC3 GENE; RET GENE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SERBIA; SOUTHERN BLOTTING; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; SERBIA; THYROID NEOPLASMS;

EID: 79958064993     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-054     Document Type: Article

References (41)

1. Rieslag MD, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (2007) SEER Cancer Statistics Review, 1975-2004. National Cancer Institute, Bethesda.
2. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and fol-licular thyroid cancer. Am J Med 97: 418-428.
3. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, Haglund C (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26: 57-64.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
5. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafci AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M (2005) The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068-1081.
6. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397.
7. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E (2006) Genotyping of anItalian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 64: 105-109.
8. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G (2002) Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963: 116-121.
9. Tallini G, Asa SL (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8: 345-354.
10. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A, Pacini F (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86: 3211-3216.
11. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S (2004) Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4280-4284.
12. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffn A (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246: 466-470.
13. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404.
14. Oler G, Ebina KN, Michaluart P, Jr., Kimura ET, Cerutti J (2005) Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 62: 509-511.
15. Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Jr., Zhang L, Fagin JA (2005) Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferenti-ation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473.
16. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S (2006) BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147: 5699-5707.
17. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL (2009) High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15: 485-491.
18. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M (2009) Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94: 1612-1617.
19. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE (2003) Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120: 71-77.
20. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG, Nikiforov YE (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326.
21. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS onco-gene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745-2752.
22. Kim CS, Zhu X (2009) Lessons from mouse models of thyroid cancer. Thyroid 19: 1317-1331.
23. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G (2003) ras mutations are associated with aggressive tumor henotypes and poor prognosis in thyroid cancer. J Clin Oncol 21: 3226-3235.
24. DeLellies RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health organization classifcation of tumors. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon.
25. Sobin LH, Wittekind CH (eds) (2002) International Union Against Cancer (UICC). TNM classifcation of malignant tumors, 6 ed. Wiley-Liss, New York.
26. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262.
27. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446: 589-595.
28. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16.
29. Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321: 86-93.
30. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95: 4197-4205.
31. Tang KT, Lee CH (2010) BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73: 113-128.
32. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S (2006) Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243: 525-532.
33. Dzodic R, Markovic I, Inic M, Jokic N, Djurisic I, Zegarac M, Pupic G, Milovanovic Z, Jovic V, Jovanovic N (2006) Sentinel lymph node biopsy may be used to support the decision to perform modifed radical neck dissection in differentiated thyroid carcinoma. World J Surg 30: 841-846.
34. Rumyantsev PO, Saenko VA, Ilyin AA, Stepanenko VF, Rumyantseva UV, Abrosimov AY, Lushnikov EF, Rogounovitch TI, Shibata Y, Mitsutake N, Tsyb AF, Yamashita S (2011) Radiation Exposure Does Not Signifcantly Contribute to the Risk of Recurrence of Chernobyl Thyroid Cancer. J Clin Endocrinol Metab 96: 385-393.
35. Lupi C GR, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F (2007) Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92: 4085-4090.
36. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97.
37. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M (2008) Papillary thyroid carcinoma: factors infuencing recurrence and survival. Ann Surg Oncol 15: 1518-1522.
38. Riesco-Eizaguirre G G-MP, García-Cabezas MA, Nistal M, Santisteban P. (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 13: 257-269.
39. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92: 2840-2843.
40. Mian C BS, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, Opocher G, Busnardo B, Girelli ME (2007) Molecular characteristics in papillary thyroid cancers (PTCs) with no (131)I uptake. Clin Endocrinol (Oxf) 68: 108-116.
41. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93: 3943-3949.